by barry101 | Apr 17, 2025 | Press Releases
HOUSTON, April 17, 2025 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viruses, today announced...
by barry101 | Apr 1, 2025 | Press Releases
– Initial data readout on track for second half of 2025 HOUSTON, April 01, 2025 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates...
by barry101 | Mar 24, 2025 | Press Releases
– Continued progress in pivotal, adaptive Phase 3 clinical trial (the “MIRACLE” trial) toward first subject treated, on track to take place in the first quarter of 2025 – Multiple subjects currently being screened in first MIRACLE site...
by barry101 | Mar 19, 2025 | Press Releases
HOUSTON, March 19, 2025 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced...
by barry101 | Mar 11, 2025 | Press Releases
On-demand video webcast now available here HOUSTON, March 11, 2025 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”) a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting...
by barry101 | Mar 10, 2025 | Press Releases
Live webcast fireside chat on Tuesday, March 18th at 11:00 AM PT HOUSTON, March 10, 2025 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug...
